Pushing the Bounds of Science
Regeneron invests in genetic medicines and antibody platforms with some mRNA collaborations. Its broad R&D scale and commercial portfolio contrast with Kernal’s narrow, early-stage focus on in vivo CAR-T.
Free
Biopharma leader advancing therapies in virology, oncology and inflammation
Precision genetic medicines for rare neuromuscular and CNS diseases